Form 4: Solventum Director Susan DeVore Receives RSU Grant

Director Susan D. DeVore was granted 3,300 restricted stock units in Solventum Corp, vesting in May 2027.

Summary

• Director Susan D. DeVore received a grant of 3,300 Restricted Stock Units (RSUs) on May 15, 2026.
• Each RSU represents a contingent right to receive one share of Solventum Corp common stock upon settlement.
• The grant is subject to a vesting schedule requiring continued service through May 15, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard equity compensation disclosure for a board member.

Risks

• Vesting is contingent upon continued service, creating a dependency on the director's ongoing tenure.

Future Outlook

The RSUs are scheduled to vest on May 15, 2027, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term oversight and alignment with shareholder interests in the healthcare technology sector.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for S&P 500 and mid-cap healthcare companies.
• Vesting periods of one year for director equity are common practice to ensure retention and commitment.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of the 3,300 RSUs on May 15, 2027.

Key Dates

Keywords

Solventum, SOLV, Form 4, Insider Trading, Director Compensation, Restricted Stock Units